Impact of the COVID-19 Pandemic on Prescription of Sacubitril/valsartan in Italy

Overview

Journal Eur J Heart Fail

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2022 Mar 18

PMID 35303393

Authors

Giuseppe M C Rosano

Simone Celant

Pier Paolo Olimpieri

Antonietta Colatrella

Graziano Onder

Andrea di Lenarda

Giuseppe Ambrosio

Gianpaolo Reboldi

Gian Franco Gensini

Furio Colivicchi

Pierluigi Russo

Affiliations

Soon will be listed here.

Abstract

Aims: The present study sought to examine the effect of the COVID-19 pandemic and lockdown measures on the prescription of sacubitril/valsartan in patients with heart failure (HF) in Italy.

Methods And Results: Data from Italian Medicines Agency (AIFA) monitoring registries were analysed. The sacubitril/valsartan monitoring registry is based on 6-month prescriptions. A monthly aggregation on new activations throughout the observational period was computed. From March to December 2020, the initiation of new HF patients on sacubitril/valsartan decreased by nearly 40% with prescriptions dropping to values similar to 2018 when the registry was still operated off-line. A slight increase in prescriptions was observed after the lockdown measures were lifted, but prescriptions remained constantly below the pre-lockdown period.

Conclusion: A marked and worrisome decline during the COVID-19 pandemic in the activation of a life-saving treatment such as sacubitril/valsartan was observed. This decline was clearly linked to the lockdown measures instated to counteract the COVID-19 pandemic. Upcoming studies should analyse the occurrence of new cases of HF as well as the severity of patients admitted to hospitals and their mortality compared to pre-pandemic levels.

Citing Articles

Treat or not treat COVID-19 with combined renin-angiotensin system and neprilysin inhibition: Have we found a solution?.

Emrich I, Bohm M Eur J Heart Fail. 2024; 27(1):148-151.

PMID: 39563085 PMC: 11798630. DOI: 10.1002/ejhf.3510.

Cause-Specific Excess Mortality During the COVID-19 Pandemic (2020-2021) in 12 Countries of the C-MOR Consortium.

Beeks V, Achilleos S, Quattrocchi A, Pallari C, Critselis E, Salameh P J Epidemiol Glob Health. 2024; 14(2):337-348.

PMID: 38775902 PMC: 11176135. DOI: 10.1007/s44197-024-00242-4.

Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis.

Kerwagen F, Riemer U, Wachter R, von Haehling S, Abdin A, Bohm M Lancet Reg Health Eur. 2023; 35:100778.

PMID: 38023333 PMC: 10652117. DOI: 10.1016/j.lanepe.2023.100778.

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.

Torti C, Olimpieri P, Bonfanti P, Tascini C, Celant S, Tacconi D Lancet Reg Health Eur. 2023; 31:100684.

PMID: 37547273 PMC: 10398591. DOI: 10.1016/j.lanepe.2023.100684.

Corrigendum to: 'An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum' and articles listed below.

Eur J Heart Fail. 2023; 25(3):444.

PMID: 36799255 PMC: 10117608. DOI: 10.1002/ejhf.2790.

References

Senni M, McMurray J, Wachter R, McIntyre H, Anand I, Duino V . Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur J Heart Fail. 2017; 20(3):491-500. DOI: 10.1002/ejhf.1054. View

Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi C, Passino C . Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis. Cardiovasc Drugs Ther. 2020; 35(5):1067-1076. DOI: 10.1007/s10557-020-07099-2. View

Sofi F, Dinu M, Reboldi G, Stracci F, Pedretti R, Valente S . Worldwide differences of hospitalization for ST-segment elevation myocardial infarction during COVID-19: A systematic review and meta-analysis. Int J Cardiol. 2021; 347:89-96. PMC: 8561779. DOI: 10.1016/j.ijcard.2021.10.156. View

Onder G, Olimpieri P, Celant S, Lenarda A, Ambrosio G, Reboldi G . Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period. Eur J Prev Cardiol. 2021; 29(4):e149-e152. PMC: 8344462. DOI: 10.1093/eurjpc/zwab096. View

Olimpieri P, Di Lenarda A, Mammarella F, Gozzo L, Cirilli A, Cuomo M . Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries. Int J Cardiol Heart Vasc. 2020; 26:100465. PMC: 6994529. DOI: 10.1016/j.ijcha.2019.100465. View

Vardeny O, Claggett B, Packer M, Zile M, Rouleau J, Swedberg K . Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016; 18(10):1228-1234. PMC: 5095784. DOI: 10.1002/ejhf.580. View

Degli Esposti L, Buda S, Nappi C, Paoli D, Perrone V . Implications of COVID-19 Infection on Medication Adherence with Chronic Therapies in Italy: A Proposed Observational Investigation by the Fail-to-Refill Project. Risk Manag Healthc Policy. 2021; 13:3179-3185. PMC: 7779805. DOI: 10.2147/RMHP.S265264. View

Colivicchi F, Di Fusco S, Magnanti M, Cipriani M, Imperoli G . The Impact of the Coronavirus Disease-2019 Pandemic and Italian Lockdown Measures on Clinical Presentation and Management of Acute Heart Failure. J Card Fail. 2020; 26(6):464-465. PMC: 7224656. DOI: 10.1016/j.cardfail.2020.05.007. View

Chan P, Girotra S, Tang Y, Al-Araji R, Nallamothu B, McNally B . Outcomes for Out-of-Hospital Cardiac Arrest in the United States During the Coronavirus Disease 2019 Pandemic. JAMA Cardiol. 2020; 6(3):296-303. PMC: 7666759. DOI: 10.1001/jamacardio.2020.6210. View

10.

Xoxi E, Facey K, Cicchetti A . The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy. Front Pharmacol. 2021; 12:699466. PMC: 8386173. DOI: 10.3389/fphar.2021.699466. View

11.

Tsao C, Lyass A, Enserro D, Larson M, Ho J, Kizer J . Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018; 6(8):678-685. PMC: 6076350. DOI: 10.1016/j.jchf.2018.03.006. View

12.

Yeoh S, Dewan P, Desai A, Solomon S, Rouleau J, Lefkowitz M . Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. ESC Heart Fail. 2020; 7(6):3355-3364. PMC: 7754973. DOI: 10.1002/ehf2.12972. View

13.

Sokolski M, Trenson S, Sokolska J, DAmario D, Meyer P, Poku N . Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. ESC Heart Fail. 2021; 8(6):4955-4967. PMC: 8653014. DOI: 10.1002/ehf2.13549. View

14.

Wosik J, Fudim M, Cameron B, Gellad Z, Cho A, Phinney D . Telehealth transformation: COVID-19 and the rise of virtual care. J Am Med Inform Assoc. 2020; 27(6):957-962. PMC: 7188147. DOI: 10.1093/jamia/ocaa067. View

15.

Giovinazzo S, Carmisciano L, Toma M, Benenati S, Tomasoni D, Sormani M . Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021; 8(5):3547-3556. PMC: 8497227. DOI: 10.1002/ehf2.13547. View

16.

Nef H, Elsasser A, Mollmann H, Abdel-Hadi M, Bauer T, Bruck M . Impact of the COVID-19 pandemic on cardiovascular mortality and catherization activity during the lockdown in central Germany: an observational study. Clin Res Cardiol. 2020; 110(2):292-301. PMC: 7680078. DOI: 10.1007/s00392-020-01780-0. View

17.

Rashid Hons M, Gale Hons C, Curzen Hons N, Ludman Hons P, De Belder Hons M, Timmis Hons A . Impact of Coronavirus Disease 2019 Pandemic on the Incidence and Management of Out-of-Hospital Cardiac Arrest in Patients Presenting With Acute Myocardial Infarction in England. J Am Heart Assoc. 2020; 9(22):e018379. PMC: 7763705. DOI: 10.1161/JAHA.120.018379. View